PAR-1 agonist also increases CCL2 and IL6 gene expression, confirming that PAR-1 activation plays a pivotal role in inflammatory processes mediated by CFs. Here, CCL2 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.